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Sir,
We would like to comment on the paper (Oei et al, 2006) which
we feel is misleading as it over-interprets data from a very small
study. The authors describe the discovery of two cases of ovarian
cancer during 1029 women years of screening. One case was a stage
3c cancer, however, this was detected at the time of the woman’s
first screen. This was therefore a prevalent case, the stage of which
could not be influenced by screening, and so no conclusions about
the efficacy of screening can be drawn from it. The second case was
a stage 2b cancer found at prophylactic bilateral salpingo-
oophorectomy 4 months after an apparently normal transvaginal
scan and CA125 result. This case would be consistent with the
suggestion from a recent meta-analysis (Hogg and Friedlander,
2004), that annual screening may not have adequate sensitivity for
the detection of early stage disease. The authors of the meta-
analysis noted the lack of reliable data in the high-risk population
to address this issue and advocated prospective trials in women at
increased genetic risk. Unfortunately, the study by Oei et al is not
adequately powered for this purpose.
Despite Oei et al’s assertion that high risk population
surveillance is ‘inefficient’, there remains a need for screening
among younger women in this group, who understandably wish to
delay prophylactic surgery in order to have children or to avoid
premature menopause. This is evidenced by the fact that 60% of
the women in the UK Familial Ovarian Cancer Screening Study
(UKFOCSS) are aged under 50 years (Rosenthal AN, personal
communication). We have recently obtained funding from Cancer
Research UK and the Eve Appeal to screen a high-risk population
of 3000 women for 5 years using 4 monthly rather than annual
CA125 testing (phase 2 of UKFOCSS). The CA125 results will be
analysed using the risk of ovarian cancer algorithm (ROCA)
(Skates et al, 2001), which has been successfully piloted in the
postmenopausal general population (Menon et al, 2005). This
algorithm has been adapted for use in the premenopausal
population and it is hoped that it will improve sensitivity and
specificity for early stage disease detection. UKFOCSS is on target
to complete recruitment by the end of 2006. There is only one
other large-scale study of high-risk population screening recruiting
worldwide. This is the US Cancer Genetics Network (CGN) study,
which is also using 4-monthly CA125 testing analysed by the
ROCA. The intention is to share data between the two studies, even
though each study is sufficiently powered to assess the perfor-
mance of screening in terms of sensitivity, specificity and positive
predictive value.
Until UKFOCSS and the CGN study report in 2012, there is
unlikely to be sufficiently reliable evidence to conclude that
familial ovarian cancer screening is effective or ineffective. We
therefore recommend that high-risk women in the US and UK
unwilling to undergo prophylactic bilateral salpingo-oophorect-
omy take part in these studies if they wish to undergo screening.
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